Evidence map›Paper›PMID 23307525›Full record

Trial reportPharmacotherapy2012

Incremental costs associated with physician and pharmacist collaboration to improve blood pressure control.

Puttarin Kulchaitanaroaj, John M Brooks, Gail Ardery, Dana Newman, Barry L Carter

Abstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Pharmacotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Impact of patient care teams on blood pressure control in patients with hypertension: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Puttarin KulchaitanaroajDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, USA.
John M Brooks
Gail Ardery
Dana Newman
Barry L Carter

Funding

University of Iowa Older Adults CERTU18HS016094 · AHRQ · UNIVERSITY OF IOWA · PI CHRISCHILLES, ELIZABETH A · 2006 to 2010
$4.0M
Improving Adherence to Blood Pressure GuidelinesR01HL070740 · NHLBI · UNIVERSITY OF IOWA · PI CARTER, BARRY L · 2003 to 2007
$3.2M
Collaborative Management of HypertensionR01HL069801 · NHLBI · UNIVERSITY OF IOWA · PI CARTER, BARRY L · 2003 to 2005
$2.0M
AHRQ HHS U18 HS016094NHLBI NIH HHS HL069801NHLBI NIH HHS HL070740NHLBI NIH HHS R01 HL069801NHLBI NIH HHS R01 HL070740PHS HHS 5U18HSO16094
6 · The paper itself

Abstract

STUDY

objectiveTo compare costs associated with a physician-pharmacist collaborative intervention with costs of usual care.

designCost analysis using health care utilization and outcome data from two prospective, cluster-randomized, controlled clinical trials.

settingEleven community-based medical offices. PATIENTS: A total of 496 patients with hypertension; 244 were in the usual care (control) group and 252 were in the intervention group. MEASUREMENTS AND MAIN

resultsTo compare the costs, we combined cost data from the two trials. Total costs included costs of provider time, laboratory tests, and antihypertensive drugs. Provider time was calculated based on an online survey of intervention pharmacists and the National Ambulatory Medical Care Survey. Cost parameters were taken from the Bureau of Labor Statistics for average wage rates, the Medicare laboratory fee schedule, and a publicly available Web site for drug prices. Total costs were adjusted for patient characteristics. Adjusted total costs were $774.90 in the intervention group and $445.75 in the control group (difference $329.16, p<0.001). In a sensitivity analysis, the difference in adjusted total costs between the two groups ranged from $224.27-515.56. The intervention cost required to have one additional patient achieve blood pressure control within 6 months was $1338.05, determined by the difference in costs divided by the difference in hypertension control rates between the groups ($329.16/24.6%). The cost over 6 months to lower systolic and diastolic blood pressure 1 mm Hg was $36.25 and $94.32, respectively.

conclusionThe physician-pharmacist collaborative intervention increased not only blood pressure control but also the cost of care. Additional research, such as a cost-benefit or a cost-minimization analysis, is needed to assess whether financial savings related to reduced morbidity and mortality achieved from better blood pressure control outweigh the cost of the intervention.

Indexed as

AgedAntihypertensive AgentsBlood PressureCluster AnalysisCooperative BehaviorCosts and Cost AnalysisDrug CostsFemaleHealth Care CostsHealth Care SurveysHumansHypertensionInterprofessional RelationsMaleMiddle AgedPharmacistsAntihypertensive Agents

Identifiers

PMID23307525
PMCPMC3545410

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.